462 related articles for article (PubMed ID: 34587385)
1. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ; Feagan BG; D'Haens G; Wolf DC; Jovanovic I; Hanauer SB; Ghosh S; Petersen A; Hua SY; Lee JH; Charles L; Chitkara D; Usiskin K; Colombel JF; Laine L; Danese S;
N Engl J Med; 2021 Sep; 385(14):1280-1291. PubMed ID: 34587385
[TBL] [Abstract][Full Text] [Related]
2. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
Sandborn WJ; Feagan BG; Wolf DC; D'Haens G; Vermeire S; Hanauer SB; Ghosh S; Smith H; Cravets M; Frohna PA; Aranda R; Gujrathi S; Olson A;
N Engl J Med; 2016 May; 374(18):1754-62. PubMed ID: 27144850
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study.
Sandborn WJ; Feagan BG; Hanauer S; Vermeire S; Ghosh S; Liu WJ; Petersen A; Charles L; Huang V; Usiskin K; Wolf DC; D'Haens G
J Crohns Colitis; 2021 Jul; 15(7):1120-1129. PubMed ID: 33438008
[TBL] [Abstract][Full Text] [Related]
4. Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study.
Feagan BG; Sandborn WJ; Danese S; Wolf DC; Liu WJ; Hua SY; Minton N; Olson A; D'Haens G
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):819-828. PubMed ID: 32553149
[TBL] [Abstract][Full Text] [Related]
5. P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study.
Hudesman D; Long M; Wolf D; Hanauer S; Ghosh S; Petersen A; Pondel M; Silver M; Cross R; Feagan B
Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S9. PubMed ID: 37461954
[TBL] [Abstract][Full Text] [Related]
6. Ozanimod: A First-in-Class Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis.
Choi D; Stewart AP; Bhat S
Ann Pharmacother; 2022 May; 56(5):592-599. PubMed ID: 34423657
[TBL] [Abstract][Full Text] [Related]
7. Ozanimod: A Review in Ulcerative Colitis.
Paik J
Drugs; 2022 Aug; 82(12):1303-1313. PubMed ID: 35994200
[TBL] [Abstract][Full Text] [Related]
8. P037 Effect of Ozanimod Treatment and Discontinuation on Absolute Lymphocyte Count in Moderate-to-Severe Ulcerative Colitis: Results from a Phase 3 Trial.
Colombel JF; D'Haens G; Irving P; Petersen A; Chitkara D; Marta C; Chen T; Charles L; Danese S; Ghosh S
Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S9. PubMed ID: 37461956
[TBL] [Abstract][Full Text] [Related]
9. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
[TBL] [Abstract][Full Text] [Related]
10. Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program.
Feagan BG; Schreiber S; Afzali A; Rieder F; Hyams J; Kollengode K; Pearlman J; Son V; Marta C; Wolf DC; D'Haens GG
Contemp Clin Trials; 2022 Nov; 122():106958. PubMed ID: 36208720
[TBL] [Abstract][Full Text] [Related]
11. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
Vermeire S; Lakatos PL; Ritter T; Hanauer S; Bressler B; Khanna R; Isaacs K; Shah S; Kadva A; Tyrrell H; Oh YS; Tole S; Chai A; Pulley J; Eden C; Zhang W; Feagan BG;
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):28-37. PubMed ID: 34798037
[TBL] [Abstract][Full Text] [Related]
12. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
D'Haens G; Dubinsky M; Kobayashi T; Irving PM; Howaldt S; Pokrotnieks J; Krueger K; Laskowski J; Li X; Lissoos T; Milata J; Morris N; Arora V; Milch C; Sandborn W; Sands BE;
N Engl J Med; 2023 Jun; 388(26):2444-2455. PubMed ID: 37379135
[TBL] [Abstract][Full Text] [Related]
13. P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study.
Sands B; Pondel M; Silver M; Petersen A; Wolf D; Panaccione R; Loftus E; Colombel JF; Sturm A; D'Haens G
Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S8. PubMed ID: 37461950
[TBL] [Abstract][Full Text] [Related]
14. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
Feagan BG; Danese S; Loftus EV; Vermeire S; Schreiber S; Ritter T; Fogel R; Mehta R; Nijhawan S; Kempiński R; Filip R; Hospodarskyy I; Seidler U; Seibold F; Beales ILP; Kim HJ; McNally J; Yun C; Zhao S; Liu X; Hsueh CH; Tasset C; Besuyen R; Watanabe M; Sandborn WJ; Rogler G; Hibi T; Peyrin-Biroulet L
Lancet; 2021 Jun; 397(10292):2372-2384. PubMed ID: 34090625
[TBL] [Abstract][Full Text] [Related]
15. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
Danese S; Vermeire S; Zhou W; Pangan AL; Siffledeen J; Greenbloom S; Hébuterne X; D'Haens G; Nakase H; Panés J; Higgins PDR; Juillerat P; Lindsay JO; Loftus EV; Sandborn WJ; Reinisch W; Chen MH; Sanchez Gonzalez Y; Huang B; Xie W; Liu J; Weinreich MA; Panaccione R
Lancet; 2022 Jun; 399(10341):2113-2128. PubMed ID: 35644166
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
Comi G; Kappos L; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Ding N; Cohen JA;
Lancet Neurol; 2019 Nov; 18(11):1009-1020. PubMed ID: 31492651
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study.
Vermeire S; Danese S; Zhou W; Ilo D; Klaff J; Levy G; Yao X; Chen S; Sanchez Gonzalez Y; Hébuterne X; Lindsay JO; Higgins PDR; Cao Q; Nakase H; Colombel JF; Loftus EV; Panaccione R
Lancet Gastroenterol Hepatol; 2023 Nov; 8(11):976-989. PubMed ID: 37683686
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
Cohen JA; Comi G; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Huang V; Kappos L;
Lancet Neurol; 2019 Nov; 18(11):1021-1033. PubMed ID: 31492652
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension.
Danese S; Panaccione R; Abreu MT; Rubin DT; Ghosh S; Dignass A; Afzali A; Wolf DC; Chiorean MV; Vermeire S; Jain A; Charles L; Lawlor G; Osterman MT; Wu H; Canavan JB; Petersen A; Colombel JF; Regueiro M
J Crohns Colitis; 2024 Feb; 18(2):264-274. PubMed ID: 37651686
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
Croft NM; Faubion WA; Kugathasan S; Kierkus J; Ruemmele FM; Shimizu T; Mostafa NM; Venetucci M; Finney-Hayward T; Sanchez Gonzalez Y; Bereswill M; Lazar A; Turner D
Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):616-627. PubMed ID: 34153231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]